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Abstract
Introduction. Impairment of the enteric nervous system has been suggested to occur within the pathogen-
esis of neurodegenerative diseases. Thus, in the current study, we consider salsolinol (1-methyl-6,7-dihy-
droxy-1,2,3,4-tetrahydroisoquinoline, SAL) as a substance that can potentially induce myenteric neurodegen-
eration. 
Material and methods. Male Wistar rats were subjected to continuous intraperitoneal dosing of salsolinol 
(200 mg/kg in total) with osmotic mini-pumps for either two or four weeks. An equivalent group of rats served 
as the control. Jejunal myenteric neurons were subjected to immunofluorescence staining to detect neuron 
specific protein — protein gene product (pan-neuronal marker, PGP 9.5), nitric oxide synthase (NOS), choline 
acetyltransferase (ChAT), Bax-protein and alpha-synuclein. In search of any functional impairment within the 
gastrointestinal tract, gut motility was assessed by determining the residual solid food contents in the stomach 
and the small and large intestine transit.
Results. The myenteric neuron count, the mean size of the neuron body, the area of ganglia and the diameter 
of nerve strands were decreased in both of the salsolinol-treated groups compared with the controls. The num-
ber of NOS-positive cells was lower in the salsolinol-treated groups, while the number of ChAT-positive cells 
remained unchanged in comparison with the controls. Neurons expressing the pro-apoptotic Bax protein and 
alpha-synuclein deposits were observed among the myenteric neurons of the salsolinol-treated rats. 
Conclusions. Salsolinol evokes enteric neuronal cell death via initiation of apoptosis and leads to the formation 
of pathological aggregates of alpha-synuclein. Impairment of myenteric neurons, mainly the inhibitory motor 
neurons, might be responsible for the abnormal intestinal transit. Thus, salsolinol might be regarded as a suit-
able compound for inducing experimental enteric neurodegeneration in rats. (Folia Histochemica et Cytobio-
logica 2015, Vol. 53, No. 1, 49–61)
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Introduction
The enteric nervous system (ENS) is a specific division 
of the autonomic nervous system and appears to be 
distinctive due to its intrinsic ability to mediate reflex 
activity, even when disconnected from the central 
circuits. ENS is responsible for main patterns of gut 
behavior, including motility, blood flow, secretion and 
absorption [1, 2]. Exposure to stress, which is defined 
as an acute threat to homeostasis, results in alterations 
of the brain-gut axis ultimately leading to the develop-
ment of a broad array of gastrointestinal disorders [3]. 
Enteric failure is also thought to be involved in the 
pathophysiology of Parkinson’s disease (PD). For 
example, disturbances of gastrointestinal function 
observed in those patients, such as constipation and 
delayed gastric emptying, detract immensely from 
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quality of life, even though do not pose an imminent 
life-threatening situation. Epidemiological evidence 
has shown that gut dysfunctions even predate well-de-
fined motor symptoms [4–7]. Braak et al. proposed 
that the pathological staging of the disease should be 
directly linked to its clinical progression. According to 
their theory, environmental factors are able to cross 
the intestinal barrier, initiate the process of enteric 
neurodegeneration and then trigger its progression 
into the central nervous system [8–11]. However, it 
remains unclear how exactly such pathological pro-
cesses are initiated and promoted. 
Different toxins, such as 6-OHDA (6-hydroksydo-
pamine), MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahy-
dropyridine), paraquat, maneb and rotenone (three 
commonly used pesticides), are often used to gene-
rate enteric Parkinsonian-like neuronal degeneration 
[12–16]. Morphological and quantitative alternations 
(especially the presence of pathological alpha-synuc-
lein aggregates) in the ENS neurons, together with gut 
dysmotility, malabsorption and disrupted excretion, 
have been observed after the animals were subjected 
to those different neurotoxins. However, the pace of 
development of new animal models of Parkinson’s 
disease is still prevailing due to their flaws as well as 
difficulty to produce a model that completely incor-
porates the underlying pathological process, which is 
still imperfectly understood in PD [14, 17]. Salsolinol 
(1-methyl-6,7-dihydroxy-1,2,3,4-tetrahydroisoquinoli-
ne) might represent such a neurotoxic candidate. It can 
be easily endogenously synthesized from dopamine and 
acetaldehyde by salsolinol synthase or from dopamine 
and pyruvic acid or delivered exogenously [18–20].
The aim of our study was to evaluate the effects 
of exogenous salsolinol on the morphology and mor-
phometry of myenteric neurons in rat intestine and 
assess the related functional changes in the gastro-
intestinal tract of rats. The obtained results suggest 
that salsolinol might be regarded as an interesting 
substance for inducing experimental enteric neuro-
degeneration in rats.
Material and methods
Animals. Male albino Wistar rats (Jagiellonian University 
Medical College Animal Laboratory, Krakow, Poland), 
weighing 230–265 g at the beginning of the treatments, were 
individually housed in cages at a constant temperature of 
22–24°C under a 12:12 hour light/dark cycle. Solid chow 
(Labofeed, Kcynia, Poland) and tap water were accessible 
ad libitum. All animal experiments were approved by the 
Jagiellonian University Bioethical Committee (protocol 
number — 67/2009, 25th June 2009) and conducted in ac-
cordance with Good Laboratory Practices.
Gross behavior. The general health status and motor func-
tion of the experimental animals were evaluated daily by 
observing their in-cage behavior and during handling to look 
for any signs of dehydration, abnormal thermoregulation, ri-
gidity, bradykinesia or akinesia, dystonia or piloerection [21].
Experimental protocol. The rats were either subjected 
to continuous dosing with racemic salsolinol or served as 
controls. Salsolinol (salsolinol hydrochloride, Sigma, USA), 
at a total dose of 200 mg/kg, was dissolved in 200 μL of 
0.9% sodium chloride solution (Baxter, Warsaw, Poland) 
and delivered via osmotic mini-pumps (ALZET, Durect 
Corporation, Cupertino, CA, USA) that were implanted 
intraperitoneally. The mini-pumps were implanted under 
sodium pentobarbital anesthesia (25 mg/kg, administered 
intraperitoneally, Vetbutal, Biowet, Pulawy, Poland). One 
group (designated the Salsolinol 1 group, S1) received sal-
solinol for two weeks (osmotic mini-pump model 2002) at 
a delivery rate of 0.5 μL/h (0.250 mg of salsolinol per hour), 
while the other (Salsolinol 2 group, S2) received salsolinol 
for four weeks (osmotic mini-pump model 2004) at a delivery 
rate of 0.25 μL/h (0.125 mg of salsolinol per hour); all rats 
in both of the salsolinol-treated groups received the same 
cumulative amount of the drug. Control rats received vehicle 
in the morphological study group (C) and the functional 
study groups (C1 and C2).
According to both Fornai et al. [22] and Alvarez-Fisher 
et al. [23] only continuous intraperitoneal administration 
of a neurotoxin with an osmotic mini-pump may induce 
a neurodegenerative state in animals that mimics features 
of human disease, in much better way than an acute bolus 
injection or an intraperitoneal injection and results in lower 
acute toxicity.
At the end of the treatment period (day 15 or day 29), 
the rats were euthanized via decapitation, and fragments of 
the jejunum were removed for the morphological assessment 
of myenteric neurons.
Functional tests. One-hour stool output in response to a novel 
environment. The one-hour stool frequency was measured 
once a week after the initiation of salsolinol infusion. The 
assays were performed between 10:00 am and 12:00 pm. 
Each animal was removed from its home cage and placed in 
a clean, clear plastic cage without food or water for 1 h. Stool 
specimens were transferred to sealed tubes immediately 
after expulsion. The total stool sample was weighed to obtain 
the wet weight, then dried overnight at 65°C and weighed 
again to obtain the dry weight. The stool water content was 
then calculated as an indicator of colon water absorption. 
The results were normalized to body weight (adapted from 
a method described in Li et al. and Greene et al. [24, 25]). 
Determination of residual solid food in the stomach and gastric 
emptying. Following overnight fasting, the rats were allowed 
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free access to pre-weighed food for sixty minutes. Thirty 
minutes later, the animals were euthanized via decapitation, 
and the stomach was excised and weighed, then dried using 
filter paper after removal of its contents and weighed again. 
The amount of food in the stomach was calculated as the 
difference between the total weight of the stomach with its 
contents and the weight of the stomach wall after the con-
tents were removed, and subsequently dried (adapted from 
a method described in Li et al., Greene et al. and Anitha et 
al. [24–26]). The food pellets were weighed before and after 
the feeding period to determine the amount consumed by 
each animal and adjusted to body mass of animals (g per 
1 kg of body mass). The residual solid food in the stomach 
after 90 minutes was determined according to the following 
equation: % of residual solid food in the stomach = gastric 
content/food intake × 100. The gastric emptying during 
90 minutes was determined according to the following equ- 
ation: % of gastric emptying = (1 – gastric content/food 
intake) × 100. The water content was calculated as the 
difference between the wet and dried stomach content (%).
Measurement of small intestine transit. Following over-
night fasting, the rats were allowed free access to specially 
prepared food, consisting of a mixture of high-fat food 
(Bento-Kronen, Versele-Laga, Deinze, Belgium) and char-
coal (10:1), for 1 h. Thirty minutes later, the animals were 
euthanized via decapitation, and the small intestine was re-
moved. The whole length of the small intestine (duodenum, 
jejunum and ileum) was divided into ten equal parts, and 
the presence of charcoal was recorded macroscopically. The 
distance that the undigested food had travelled was taken as 
an estimate of transit in the small intestine. The transit was 
expressed as a percentage, with the first part of the bowel 
corresponding to 10% transit and the last part of the bowel 
to 100% transit. 
Whole-mount longitudinal muscle-myenteric plexus 
(LMMP) preparations. Whole-mount preparations were 
produced to study the morphology of rats’ myenteric plexus. 
Briefly, pieces of the proximal part of the small intestine 
(jejunum) were opened via incision along the mesenteric 
attachment, then pinned and stretched slightly on a Petri 
dish layered with Sylgard 184 (Silicone Elastomer Kit, Dow 
Corning, Midland, MI, USA) with the mucosal surface facing 
up and subsequently washed in 3 changes of 0.1 M phospha-
te-buffered saline (PBS; pH 7.4). The tissue was then fixed 
by immersion in Zamboni’s fixative [27] overnight at 4°C. 
Following a brief rinse in PBS, the tissue was washed vigoro-
usly at room temperature in several changes of 50% ethanol 
in distilled water. The removal of picric acid was complete 
after 3 to 5 changes (10 min each) of ethanol. The tissue 
was then washed in 3 to 5 changes (10 min each) of PBS. 
The mucosa, submucosa and circular muscle were then 
removed to facilitate the penetration of antibodies to the 
myenteric plexus under the S4E stereomicroscope (Leica, 
Wetzlar, Germany) with an Intralux 5100 light source (Volpi 
AG, Schlieren, Switzerland) using appropriate clamps and 
fine scissors. Whole-mount preparations containing longi-
tudinal muscle and myenteric plexus (LMMP) were rinsed 
in PBS and cut into pieces of approximately 5 mm × 5 mm. 
A heat-induced antigen retrieval protocol was applied to 
unmask antigen determinants by immersion of the slides 
(free floating) in a water bath at 90–95°C in DAKO Target 
Retrieval Solution (Dako, Glostrup, Denmark) for 20 min. 
Immunofluorescence. Whole-mount preparations were incu-
bated for 30 min in PBS with appropriate normal serum and 
0.3% Triton X-100 (Sigma-Aldrich, St. Louis, MO, USA) 
at room temperature, followed by overnight incubation at 
4°C in a solution of PBS with appropriate normal serum 
containing the primary antibody and 0.3% Triton X-100. 
Following 5 washes (10 min each) in PBS, the whole mo-
unts were incubated for 1 h at room temperature with the 
secondary antibody diluted in PBS with appropriate normal 
serum and 0.3% Triton X-100. Finally, the whole-mount 
preparations were washed in two changes (10 min each) of 
PBS and mounted on gelatin-coated slides, air-dried, and 
cover-slipped with UltraCruz Mounting Medium (Santa 
Cruz Biotechnology, Dallas, TX, USA). Afterwards, the 
labeled whole mounts were analyzed immediately. 
Antisera for immunofluorescence. The following primary 
antisera were used (Table 1): anti-PGP 9.5 (pan-neuronal 
marker — protein gene product, Dako); anti-NOS (nitric 
oxide synthase, Santa Cruz Biotechnology); anti-ChAT 
(choline acetyltransferase, Merck Millipore, Darmstadt, 
Germany); anti-TH (tyrosine hydroxylase, Millipore); anti-TH 
(tyrosine hydroxylase, Santa Cruz Biotechnology); and 
anti-alpha-synuclein (BD Bioscience, San Jose, CA, USA).
The following secondary antibodies were used (Table 1): 
polyclonal donkey anti-goat/FITC (Santa Cruz Biotechnolo-
gy); FITC-conjugated polyclonal swine anti-rabbit (Dako); 
RPE-conjugated polyclonal goat anti-mouse (Dako); 
Cy3-conjugated polyclonal goat anti-rabbit (Jackson, West 
Grove, PA, USA); and biotinylated goat anti-mouse together 
with FITC-conjugated streptavidin (Jackson). The quality of 
Jackson’s secondary antibodies used in the experiment was 
already extensively and successfully examined [28].
Detection of the Bax protein. To visualize apoptosis, jejunal 
tissue fragments were ﬁxed in formalin (8% formaldehyde 
in 0.1 M phosphate buffer, pH 7.4), and parafﬁn-embedded 
5 μm slices were prepared. A heat-induced antigen retrieval 
protocol was applied to unmask antigen determinants via 
immersion of the slides in a water bath at 90–95°C in DAKO 
Target Retrieval Solution for 20 min. The sections were 
first pre-treated with Protein Block Serum Free (Dako) 
and 0.3% Triton X-100 at room temperature for 30 min to 
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block non-specific binding, and then incubated overnight 
at 4°C with a primary polyclonal rabbit anti-Bax antibody 
(Calbiochem/Merck Millipore, Darmstadt, Germany) in 
DAKO Dilution Solution (Dako). Following incubation with 
the primary antibody, the sections were washed with 0.1 M 
phosphate buffer and processed using the LSAB2 (Dako) 
visualization kit with 3,3’-diaminobenzidine (DAB, Dako) 
as a chromogen, according to the manufacturer’s instruc-
tions. The specimens were cover-slipped with glycerol and 
analyzed immediately. 
Image analysis. All images were obtained using either an 
AXIOPHOT light microscope (Zeiss, Jena, Germany) or 
a JENAMED 2 fluorescence microscope (Zeiss, Jena, Ger-
many) equipped with a ProgRes C12 plus digital camcorder 
(Jenoptik, Jena, Germany). Only the anti-mesenteric aspect 
of the jejunum was sampled. Digital images were collected 
at 250 × magniﬁcation and quantified using computer-ba-
sed image analysis system Multiscan 18.03 software (CSS, 
Warsaw, Poland). In order to calibrate the software (semi- 
-automatic measurement), the Bürker chamber was placed 
on the microscope stage and the counting grid was brought 
into focus. The measured area of the microscopic field of 
vision (0.391 mm2) was used to perform all the calculations. 
Cell counting was performed in a blinded manner on coded 
slides, to avoid bias.
To classify the observed ganglionic organization, the 
number of PGP 9.5-positive neurons (at least 100 neurons 
per whole mount, expressed as number of cells/mm2), the 
size of the neuron body (this term refers to the area of the 
maximal profile seen in the whole-mount preparations, μm2), 
the diameter of the nerve fibers (at least fifty nerve fibers 
per whole mount, with only primary internodal strands 
being taken into account, μm) and the relative ganglionic 
area (excluding nerve fibers, %) were semi-automatically 
measured in ten randomly chosen, non-overlapping micro-
scopic fields per animal. All stained cells were identified as 
the nerve cells on the basis of their morphology, showing 
a round or ovoid nucleus and a clear profile. 
To quantify the subclasses of myenteric neurons (NOS-
-positive, ChAT-positive, TH-positive), the positively stained 
cells were semi-automatically measured in ten randomly 
chosen, non-overlapping microscopic fields per animal. The 
stained cells were identified as the nerve cells on the basis 
of their morphology, showing a round or ovoid nucleus and 
a clear profile. The final numbers were expressed as the 
number of neurons per 1 mm2 and as the percentage of the 
total number of PGP 9.5-positive neurons.
The number of alpha-synuclein-immunopositive cells 
co-reactive for PGP 9.5 was determined semi-automatically 
in ten randomly chosen, non-overlapping microscopic fields 
per animal and expressed as the number of alpha-synuclein-
-positive neurons per 1 mm2.
The number of Bax-immunopositive neurons in the 
myenteric area was determined semi-automatically in ten 
randomly chosen, non-overlapping microscopic fields per 
animal and expressed as the number of Bax-positive neurons 
per 1 mm2.
Table 1. Types, sources and dilution of antibodies
Antibody Catalog number and company Dilution
Primary antibodies
Polyclonal rabbit anti-PGP 9.5 Z5116, Dako 1:200
Polyclonal goat anti-NOS sc-49055, Santa Cruz 1:100
Polyclonal rabbit anti-ChAT AB143, Millipore 1:150
Monoclonal mouse anti-TH AB318, Millipore 1:200
Monoclonal mouse anti-TH sc-47708, Santa Cruz 1:100
Polyclonal rabbit anti-c-Kit A4502, Dako 1:150
Polyclonal rabbit anti-Bax PC66, Calbiochem 1:200
Monoclonal mouse anti-a-synuclein 610787, BD Bioscience 1:500
Secondary antibodies
FITC-conjugated polyclonal donkey anti-goat J2609, Santa Cruz 1:40
FITC-conjugated polyclonal swine anti-rabbit F0205, Dako 1:100
RPE-conjugated polyclonal goat anti-mouse R0480, Dako 1:40
Cy3-conjugated polyclonal goat anti-rabbit 111-165-144, Jackson 1:500
FITC-conjugated streptavidin 016-010-084, Jackson 1:400
Biotinylated goat anti-mouse 115-065-146, Jackson 1:500
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Statistical analysis. All data are expressed as the mean and 
standard deviation (SD). The results were analyzed via one-way 
analysis of variance (ANOVA), followed by post-hoc tests (Tu-
key’s test) using the STATISTICA 9.0 software package (Stat-
Soft, Tulsa, USA). Statistical significance was set at p < 0.05.
Results
Gross behavior
None of the salsolinol-treated animals in any of the 
experiments died or showed any visible disturbances 
or discomfort to any significant degree. No disturban-
ce of gross motor function was observed in any of the 
salsolinol-treated rats. 
Morphology and morphometry  
of the jejunal myenteric plexus neurons
The jejunal myenteric plexus was readily detected 
in whole-mount preparations stained to detect 
pan-neuronal marker PGP 9.5. Regardless of the 
experimental group, the neurons of the myenteric 
plexus, located between the circular and longitudinal 
muscle layers, retained their ganglionic organization, 
showing elongated and triangular arrangements. The 
ganglia of the myenteric plexuses of control animals 
were mainly oriented with their long axis parallel to 
the circular muscle layer. Consistent intense staining 
of the neuronal somata, nuclei and the majority of 
neuronal processes was observed (Figure 1D). Most 
of the neurons were round and formed groups of 
heterogeneous size.
The whole-mount preparations from the salsoli-
nol-treated groups displayed irregular morphological 
disruptions in the ganglia of the jejunal myenteric 
plexus. Ganglia displaying empty areas (“cavities”) 
could be observed [29]. Isolated nerve cells or ganglia 
with only a small number of nerve cells were observed 
as well (Figure 1B, C).
The number of myenteric neurons (PGP 9.5-positi-
ve), the size of the neuron bodies (Figure 2) and the 
diameter of the nerve fibers (only primary internodal 
strands were taken into account) were significantly 
decreased in both of the salsolinol-treated groups 
in comparison with the control group (Table 2). De-
crease in the population of larger neurons (around 
400 μm2) and increase in the population of smaller 
neurons (around 200 μm2) was observed in salsoli-
nol-treated animals (Figure 2). The ganglionic area 
(excluding nerve fibers) in the myenteric plexus was 
reduced by 6% and 23% in rats treated with salsolinol 
for two (S1 group) or four (S2 group) weeks, respec-
tively, in comparison with the control group. 
Morphometric analysis of the jejunal  
myenteric plexus motor neurons
It was found that ChAT-positive neurons (choliner-
gic neurons) and NOS-positive neurons (nitrergic 
Figure 1. Pan-neuronal marker PGP 9.5 immunoreactivity in the jejunal myenteric plexus. Representative photomicro-
graphs show the immunoreactivity of the pan-neuronal marker PGP 9.5 in the whole mounts of the jejunal myenteric 
plexus of the salsolinol-treated for two (A, Cy3 staining) or four weeks (B, C, fluorescein staining) and control adult Wi-
star rats (D, Cy3). Arrows (B, C) indicate abnormal cavities [29] within the ganglia of the jejunal myenteric plexus of rats 
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neurons) are the two non-overlapping chemical 
phenotypes that collectively account for almost the 
entire population of neurons in the myenteric plexus. 
The mean number of NOS-positive neurons per 
1 mm2 of the jejunal myenteric plexus was significantly 
lower in the S1 (p < 0.05) and S2 (p < 0.001) groups 
than the control group (Figure 3A). Tukey’s test sho-
wed no differences between the S1 and S2 groups. The 
mean number of ChAT-positive neurons per 1 mm2 
of the jejunal myenteric plexus did not differ between 
any of the experimental groups (Figure 3C).
However, the mean percentage of PGP 9.5-positi-
ve myenteric neurons expressing NOS immunoreacti-
vity remained unchanged (Figure 3B), while the mean 
percentage of PGP 9.5-positive myenteric neurons 
expressing ChAT immunoreactivity was slightly in-
creased (however, statistically insignificant) in both 
of the salsolinol-treated group of rats in comparison 
with the control animals (Figure 3D).
Morphometric analysis of TH-positive  
neurons in the jejunal myenteric plexus 
Two different monoclonal antisera (Table 1) were 
used in our experiment to visualize the dopaminergic 
population of the jejunal myenteric plexus ganglia. 
However, no cell bodies were visible, with only the 
dense architecture of the nerve fibers being stained, 
and no differences were observed between any of the 
experimental groups.
Alpha-synuclein expression  
in jejunal myenteric neurons
The pattern of alpha-synuclein expression in the jeju-
nal myenteric plexus in the salsolinol-treated rats was 
clearly visible and consistent (Figure 4). A subpopu-
lation of myenteric neurons was immunopositive for 
alpha-synuclein, with the protein being detected in 
Table 2. Morphometric analysis of the myenteric plexus in the jejunum of the salsolinol-treated and control rats
Groups of rats
S1 S2 C
Number of neurons [per mm2] 103.04 ± 37.5* 103.95 ± 26.1* 131.40 ± 42.3
Neuronal somatic area [μm2] 0306.32 ± 104.3* 231.34 ± 81.8* 330.55 ± 98.9
Diameter of nerve fibers [μm] 16.46 ± 3.2* 15.74 ± 3.1* 17.85 ± 3.4
Adult Wistar rats were treated with salsolinol for two (S1) or four (S2) weeks or not treated (C, control). Each group included 8 animals. Data are 
expressed as the mean ± SD; *statistically significant vs. control group, p < 0.05
Figure 2. Distributions of the cell body areas of PGP 9.5-immunoreactive neurons in the jejunal myenteric plexus in the 
salsolinol-treated and control rats. Histogram displaying the distributions of the cell body areas of PGP 9.5-immunoreac-
tive neurons in the jejunal myenteric plexus of the salsolinol-treated for two (S1) or four (S2) weeks and control (C) adult 
Wistar rats. Each group included 8 animals
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the cytoplasm as well as the nucleus. Alpha-synuclein-
-positive varicosities occurred within ganglia and en-
circled individual neurons. Quantitative comparison 
showed an increase in alpha-positive neurons within 
1 mm2 of the jejunal myenteric plexus in the salsoli-
nol-treated rats [S1 (7.433/mm2 ± 4.032; p < 0.001; 
n = 8) and S2 (6.424/mm2 ± 4.081; p < 0.001; n = 8)] 
in comparison with control group C (2.661/mm2 ± 
1.764, n = 8). Tukey’s test showed no differences 
between the S1 and S2 groups. 
Bax protein expression in jejunal neurons  
of the myenteric plexus
Immunohistochemical staining to detect Bax (Figure 5), 
a pro-apoptotic member of the Bcl-2 family of pro-
teins, revealed a marked increase in the number of 
Bax-immunopositive cells among myenteric neurons 
in the S2 group of rats (1.095/mm2 ± 1.82; p < 0.05; 
n = 8) in comparison with the control group C 
(0.256/mm2 ± 0.78; n = 8). Tukey’s test showed 
no differences between the S1 (0.894/mm2 ± 1.47; 
n = 8) and control or S2 groups. 
Measurement of one-hour stool output
The mean dry weight of the fecal output of the salsoli-
nol-treated S2 group (p < 0.01) was markedly elevated 
between the 1st and 7th day of the experiment in com-
parison with the control and the S1 groups (Table 3). 
The mean dry weight of the fecal output between the 
8th and 14th day of the experiment was lower in the 
salsolinol-treated S2 group in comparison with the con-
trol C2 group and was markedly lower in the S1 group 
(p < 0.05) in comparison with the C1 group (Table 3).
Among the salsolinol-treated groups of rats, the 
mean stool water content was significantly lower in the 
S2 group (p < 0.05) in comparison with the control 
C2 group between the 8th and 14th days and between 
15th and 28th days of the experiment (Table 3). 
Figure 3. Morphometry of the jejunal myenteric plexus in the salsolinol-treated and control rats. Analysis of the myenteric 
plexus morphometry in the jejunum of the salsolinol-treated for two (S1) or four (S2) weeks and control (C) adult Wistar 
rats. Each group included 8 animals. A. Number of NOS-positive neurons within 1 mm2 of the jejunal myenteric plexus;  
B. Percentage of PGP 9.5-positive myenteric neurons expressing NOS immunoreactivity; C. Number of ChAT-positive 
neurons within 1 mm2 of the jejunal myenteric plexus; D. Percentage of PGP 9.5-positive myenteric neurons expressing 
ChAT immunoreactivity. Data are expressed as the mean ± SD; *statistically significant vs. control group, p < 0.05
A B
C D
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Figure 4. Alpha-synuclein immunoreactivity in the jejunal myenteric plexus. Representative photomicrographs showing 
the immunoreactivity for alpha-synuclein in the whole mounts of the jejunal myenteric plexus of adult Wistar rats treated 
with salsolinol for four weeks. Fluorescein staining. Total magnification: A, × 200; B, × 400; scale bar, 50 μm
A
Figure 5. Bax immunoreactivity in the jejunal myenteric plexus. Representative photomicrographs show Bax immunoreac-
tivity for Bax in the jejunal myenteric plexus of adult Wistar rats treated with salsolinol for four weeks (A) and untreated 
control animals (B). Total magnification: × 400; scale bar, 50 μm
A
Measurement of residual solid food  
in the stomach and gastric emptying
The amount of food consumed within the one-hour 
testing period did not differ between the salsolinol-
-treated and control groups of rats (Table 4). The per-
centage of mean residual solid food in the stomachs 
of the S1 group (p < 0.05) was significantly higher 
than in the C1 group (Table 4), but no differences 
between the S2 and C2 groups or the S1 and S2 groups 
B
B
57Salsolinol affects myenteric plexus neurons
©Polish Society for Histochemistry and Cytochemistry
Folia Histochem Cytobiol. 2015
10.5603/FHC.a2015.0010
www.fhc.viamedica.pl
derivatives in the brain since so far alkaloids had been 
considered to occur only in plants and had never been 
considered as a potential pathophysiological factor 
in PD [20]. The metabolism of salsolinol has been 
relatively well described [20, 30, 31]. The distribu-
tion of the N-methylated and oxidized byproducts 
of salsolinol likely follow a certain pattern in the 
human nigrostriatal pathway and should therefore 
regulate the function of dopaminergic neurons [32]. 
Thus far, salsolinol and its metabolite N-methyl-sal-
solinol have been related to the neurodegeneration 
of central dopaminergic circuits and associated with 
the pathogenesis of Parkinson disease [19, 20, 33–35]. 
We decided to investigate the salsolinol treatment as 
an experimental model in order to mimic gastrointe-
stinal changes observed in patients with Parkinson’s 
disease, in accordance with the Braak’s hypothesis.
In the present study, subacute treatment with 
salsolinol caused a destructive effect on the my-
enteric neurons since number of PGP 9.5-positive 
neurons, the size of the neuron bodies and the 
diameter of the nerve fibers were significantly de-
creased in both of the salsolinol-treated groups in 
comparison with the control group. Decrease in 
the population of larger neurons (around 400 μm2) 
Table 3. Cumulative fecal output and stool water content in the salsolinol-treated and control rats
Groups of rats
S1 C1 S2 C2
Dry weight [mg]a 1.44 ± 0.51 1.43 ± 0.29 02.20 ± 0.31* 1.678 ± 0.37
Water (%)a 58.39 ± 14.54 53.37 ± 10.64 56.56 ± 10.98 56.26 ± 5.51
Dry weight [mg]b 01.21 ± 0.37* 1.61 ± 1.14 0.96 ± 0.17 01.01 ± 0.23
Water (%)b 51.34 ± 13.47 53.23 ± 19.72 47.70 ± 7.22* 059.95 ± 10.97
Dry weight [mg]c – – 0.84 ± 0.08 00.82 ± 0.38
Water (%)c – – 63.96 ± 5.47* 67.07 ± 2.84
Cumulative fecal output (dry weight, mg) and stool water content (%) in adult Wistar rats treated with salsolinol for two (S1) or four weeks (S2) 
and relevant control animals (C1, C2), between the (a) 1–7th, (b) 8–14th, and (c) 15–28th days of the experiment. Each group included 8 animals. 
Data are expressed as the mean ± SD; *statistically significant vs. relevant control group, p < 0.05
were found. Similarly, the percentage of the gastric 
emptying between the salsolinol-treated and control 
rats (Table 4) remained unchanged as well.
The mean water content in the gastric contents 
was significantly lower in the S1 (p < 0.05) group 
in comparison with the C1 group. There were no 
differences between the S2 and C2 or the S1 and S2 
groups (Table 4).
Measurement of small intestine transit
The presence of charcoal was recorded in either the 
9th segment (corresponding to 90% transit) or 10th seg-
ment (corresponding to 100% transit) of the intestine 
in the rats from the four experimental groups (S1, S2, 
C1, C2; n = 8 each). The mean small intestine motility 
observed in the salsolinol-treated rats did not differ 
significantly (S1 = 97.5%; S2 = 95%) from control 
rats (C1 = 100%; C2 = 97,5%). 
Discussion
Salsolinol was detected for the first time in urine of 
Parkinsonian patients administered with L-DOPA 
in 1970s. This finding stimulated the studies on SAL 
Table 4. Residual solid food in the stomach and gastric emptying in the salsolinol-treated and control rats
Groups of rats
S1 C1 S2 C2
Food intake during 60 min (g per 1kg of body mass) 16.4 ± 3.5 19.6 ± 2.5 14.8 ± 6.0 15.4 ± 2.2
Residual solid food (%) 080.2 ± 6.1 * 68.4 ± 6.1 81.3 ± 4.4 73.6 ± 6.8
Water content (%) 045.0 ± 3.4 * 52.0 ± 3.7 49.3 ± 4.2 51.8 ± 3.2
Gastric emptying after 90 min (%) 55.0 ± 3.1 48.4 ± 3.0 50.7 ± 3.8 56.1 ± 7.1
Food intake (g per 1 kg of body mass) during 60 min, residual solid food in the stomach (%), water content (%) and gastric emptying after  
90 min (%) in adult Wistar rats treated with salsolinol for two (S1) or four weeks (S2) and relevant control animals (C1, C2). Each group  
included 8 animals. Data are expressed as the mean ± SD; *statistically significant vs. relevant control group, p < 0.05
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and increase in the population of smaller neurons 
(around 200 μm2) was observed in salsolinol-tre-
ated animals as well. The ganglionic area in the 
myenteric plexus was also reduced in the salsolinol- 
treated animals. Conversely, unilateral treatment 
with 6-hydroxydopamine did not affect the total 
number of HuC/D-immunopositive (human neuronal 
protein) myenteric neurons in the proximal and distal 
segments of the ileum and colon of rats according to 
Blandini et al. [16].
Myenteric neuron shrinkage together with an 
increased number of myenteric neurons expressing 
Bax protein observed in our experiment might also 
suggest that the observed effect was mediated thro-
ugh the induction of apoptotic pathways. Evidence 
for the role of apoptotic cell death in PD arises from 
morphological and molecular studies in cell cultures, 
animal models, as well as human studies on postmor-
tem brains from Parkinsonian patients [36, 37]. Bax is 
a primary effector of cell death that translocates from 
the cytosol to the mitochondria upon stress, where it 
facilitates cytochrome c release and the subsequent 
caspase cascade activation [38]. Some experiments 
showed that Bax is an important regulator of apoptotic 
neurodegeneration and that Bax plays a pivotal role in 
the destruction of dopamine-producing neurons in a 
mouse model of PD [39]. In MPTP (1-methyl-4-phe-
nyl-1,2,3,6-tetrahydropyridine)-injected mice Bax 
expression levels were increased in regions specifically 
affected by the neurodegeneration processes [39, 40]. 
So far, Naoi et al. demonstrated the cell death caused 
by salsolinol in human dopaminergic neuroblastoma 
SH-SY5Y cells to be apoptotic [18]. Apoptosis caused 
by this neurotoxin is thought to be mediated by an 
intracellular sequential process, loss of mitochondrial 
membrane potential, activation of caspases and DNA 
fragmentation [18, 41]. 
According to functional classification, enteric 
motor neurons are either inhibitory (e.g. NOS-po-
sitive neurons) or excitatory (e.g. ChAT-positive 
neurons). The guinea pig has become a model spe-
cies for identifying these neuron types in the enteric 
nervous system [42]. However, there are differences 
in quality and quantity of enteric neurons between 
different species. This heterogeneity is further rela-
ted to the thickness of the gut wall or the amount 
of connective tissue present. Different factors influ-
ence the quality of whole-mount preparations and 
the penetration of antibodies, resulting in different 
staining intensities [43].
In our experiment, we observed a statistically 
significant decrease in the number of NOS-positive 
(nitrergic) neurons in the jejunal myenteric plexus. 
This finding is consistent with the results of 6-hydroxy-
dopamine treatments, which reduced the number 
of nitrergic neurons in the distal ileum and proxi- 
mal colon in rodents [16]. The average integrated 
optical densities of nNOS-positive areas in the ga-
stric antrum and colon tissue are decreased in rats 
with unilateral 6-hydroxydopamine lesions [44]. 
However, treatment through either intraperitoneal 
injection of MPTP [45] or continuous subcutaneous 
administration of rotenone [25] was found to cause no 
alterations in the numbers or morphology of nitrergic 
neurons. Thus, our data might suggest that salsolinol 
exerts stronger toxic effect on nitrergic neurons than 
MPTP or rotenone. 
Furthermore, salsolinol caused no alterations in 
jejunal ChAT-positive (cholinergic) neuron numbers. 
Similarly, no changes in cholinergic neurons were 
observed in rats with brain unilateral 6-hydroxydo-
pamine lesions [44], and there were no differences in 
the density of these neurons found in the MPTP [45] 
or rotenone [25] models. 
Treatment with intraperitoneal injections of 
MPTP has been reported to cause a 40% reduction 
of the number of dopaminergic neurons in the ENS 
of mice, and a relaxation defect in the colon of these 
animals was confirmed by the electrophysiological re-
cordings [45]. Unilateral 6-hydroxydopamine lesions 
increase the average integrated optical densities of 
TH-positive areas in the gastric antrum and colon 
tissue of rats [44]. In our experiment, we did not ob-
serve any TH-positive neurons (cell bodies) localized 
within the jejunal myenteric plexus. However, a dense 
network of TH-positive fibers was clearly visible. In 
fact, there is no direct evidence that dopaminergic 
neurodegeneration should play a fundamental role in 
ENS neurodegeneration. Rather, intrinsic inhibitory 
neural pathways are expected to be critical for the 
gastrointestinal dysfunctions observed in Parkinso-
nian patients.
Rotenone administered subcutaneously with 
osmotic pumps induces a delay in gastric emptying 
and a transient decrease in stool frequency [25]. Rats 
with unilateral 6-hydroxydopamine lesions in the 
nigrostriatal dopaminergic neurons display marked 
inhibition of the propulsive activity. Blandini et al. 
suggested that this inhibition is a consequence of 
the impairment of nitric oxide-mediated descending 
inhibition during peristalsis [46]. In the same model, 
Zhu et al. reported a decrease in the weight and 
water content of the fecal matter and an increase 
in the percentage of residual solid food. Lesioned 
rats showed delayed gastric emptying and constipa- 
tion [44]. In the present study, we noted a decrease 
in transit in the large intestine. Furthermore, there 
was a notable decrease in water content, especially in 
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rats treated with salsolinol for four week, which might 
be associated with the loss of NOS-positive neurons. 
However, we did not detect any disturbances in small 
intestine transit. The salsolinol-treated animals also 
presented reduced gastric emptying and decreased 
water content of the gastric residues. 
Gastrointestinal symptoms are prominent and 
disabling manifestations of Parkinson’s disease [7, 
46–48]. Some such manifestations, such as consti-
pation, may precede somatic motor symptoms by 
many years [4]. Neuropathologic studies consistently 
demonstrate the involvement of the enteric nervous 
system [9, 49–52] and the dorsal motor nucleus of 
the vagus (DMV) based on alpha-synuclein histo-
pathology [53, 54]. These symptoms are classified 
as drooling, pharyngeal or esophageal dysmotility, 
early satiety and nausea, constipation and defecatory 
dysfunction, as elegantly summarized in a review by 
Cerosimo and Benaroch [55]. Chronic constipation 
most likely reflects a loss of neurons in the myenteric 
plexus [56, 57] and may also occur as a manifestation 
of the age-related neurodegeneration of the ENS [58]. 
Thus, reduced colonic transit is likely to reflect the 
involvement of myenteric neurons in PD [9, 50]. 
Siddiqui et al. confirmed that autonomic dysfunction 
occurs in PD patients at a greater frequency and with 
a greater severity than in comparably aged controls [59]. 
It appears that gastrointestinal dysfunction might be 
a direct consequence of enteric neuron pathology and 
neurotransmitter impairment [8, 9, 59] or an indirect 
consequence of the pathology of the substantia nigra 
and striatum [60, 61]. Several observations reported 
to date support the well-known Braak hypothesis [10, 
62–64]. This pathology is expected to start in the ga-
stric submucosal plexus [9] and spread to the central 
nervous system via axons of the DMV [11].
There are parallels between brain and enteric 
neurons. Pathology induced by alpha-synuclein 
analogous to that described in the CNS has been 
demonstrated in the gut. The formation of such 
aggregates is believed to depend on the presence 
of either genetically abnormal proteins or normal 
proteins that undergo a change in structure due to 
being present in excess, exceeding their clearance 
ability [65, 66]. Alpha-synuclein-positive inclusions 
form Lewy bodies which were detected in the my-
enteric plexuses of PD patients, particularly within 
enteric inhibitory motor neurons [9, 17, 50, 67]. 
These inclusions have also been detected in non- 
-symptomatic subjects with PD-related brain lesions 
limited to the lower brainstem, thereby supporting 
the hypothesis that the gastrointestinal tract may be 
an early target of the disease [11]. In our experiment, 
salsolinol induced alpha-synuclein aggregation within 
the myenteric neurons. Similar accumulation was ob-
served after 6-hydroxydopamine administration [68].
The presence of alpha-synuclein inclusions in VIP- 
-positive [51] and NOS-positive neurons suggests that 
reduced transit in the large intestine may result from 
disturbed smooth muscle relaxation due to the loss of 
inhibitory motor neurons [16, 44]. Therefore, both the 
constipation and the delay gastric emptying observed 
in PD patients are expected to be caused by impaired 
descending inhibition, mediated by nitric oxide during 
peristalsis. Impairment of enteric nitrergic neurons 
could induce over-contraction of smooth muscle, 
leading to muscle spasm and slow colon motility, 
increasing water absorption from intestinal contents 
[44, 69]. Interestingly, we also observed a decrease in 
body weight gain and slower adipose tissue accumu-
lation in the salsolinol-treated animals, which may 
result from abnormal gastrointestinal motility and 
absorption [70].
In conclusion, our results confirm the role of 
inhibitory motor neurons in the pathogenesis of 
gastrointestinal dysfunctions, similar to the findings 
of other experimental studies. These results also sug-
gest that endogenous neurotoxins, such as salsolinol, 
might lead to the accumulation of alpha-synuclein 
aggregates in the ENS neurons and may be useful in 
experiments elucidating the pathomechanisms of the 
neurodegenerative processes.
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